{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:21:29Z","timestamp":1791037289535,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010486","name":"Teijin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016242","name":"Boston Scientific Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jcin.2022.01.019","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T14:57:31Z","timestamp":1647874651000},"page":"630-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice"],"prefix":"10.1016","volume":"15","author":[{"given":"Osamu","family":"Iida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terutoshi","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizo","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Ichihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Nanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2022.01.019_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","article-title":"Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial","volume":"11","author":"Schneider","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2022.01.019_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jcin.2018.02.019","article-title":"Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT global study","volume":"11","author":"Micari","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.01.019_bib3","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jvs.2019.02.030","article-title":"Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts","volume":"70","author":"Shishehbor","year":"2019","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jcin.2022.01.019_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(18)32262-1","article-title":"A\u00a0polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial","volume":"392","author":"Gray","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2022.01.019_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00270-020-02693-1","article-title":"Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent","volume":"44","author":"M\u00fcller-H\u00fclsbeck","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jcin.2022.01.019_bib6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.01.019_bib7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jcin.2018.03.046","article-title":"1-year all-comers analysis of the Eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty","volume":"11","author":"Bisdas","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.01.019_bib8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2014.12.036","article-title":"Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC)","volume":"65","author":"Patel","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.01.019_bib9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jcin.2015.03.022","article-title":"1-year results of the ZEPHYR Registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis","volume":"8","author":"Iida","year":"2015","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.01.019_bib10","first-page":"S1","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"43","author":"Norgren","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jcin.2022.01.019_bib11","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jcin.2022.01.019_bib12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jvs.2010.03.050","article-title":"Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent","volume":"52","author":"Soga","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jcin.2022.01.019_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1358863X20987894","article-title":"Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia","volume":"26","author":"Kum","year":"2021","journal-title":"Vasc Med"},{"key":"10.1016\/j.jcin.2022.01.019_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1526602820901723","article-title":"Effectiveness and safety of a paclitaxel-eluting stent for superficial femoral artery lesions up to 190\u00a0mm: one-year outcomes of the single-arm IMPERIAL long lesion substudy of the Eluvia drug-eluting stent","volume":"27","author":"Golzar","year":"2020","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jcin.2022.01.019_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2011.09.036","article-title":"Classification and clinical impact of restenosis after femoropopliteal stenting","volume":"59","author":"Tosaka","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.01.019_bib16","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jcin.2016.01.007","article-title":"The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions","volume":"9","author":"Iida","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.01.019_bib17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jvs.2013.10.050","article-title":"Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions","volume":"59","author":"Dohi","year":"2014","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jcin.2022.01.019_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jvir.2021.02.014","article-title":"Vascular response of a polymer-free paclitaxel-coated stent (Zilver PTX) versus a polymer-coated paclitaxel-eluting stent (Eluvia) in healthy swine femoropopliteal arteries","volume":"32","author":"Sakamoto","year":"2021","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jcin.2022.01.019_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41569-019-0234-x","article-title":"Drug-eluting coronary stents: insights from preclinical and pathology studies","volume":"17","author":"Torii","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2022.01.019_bib20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2010.05.066","article-title":"Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.01.019_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002730","article-title":"Femoropopliteal artery stent thrombosis: report from the excellence in peripheral artery disease (XLPAD) registry","volume":"9","author":"Banerjee","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2022.01.019_bib22","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.4244\/EIJ-D-19-00187","article-title":"Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery","volume":"15","author":"Bradaric","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2022.01.019_bib23","doi-asserted-by":"crossref","first-page":"219389","DOI":"10.1155\/2012\/219389","article-title":"Pathological perspective of drug-eluting stent thrombosis","volume":"2012","author":"Inoue","year":"2012","journal-title":"Thrombosis"},{"key":"10.1016\/j.jcin.2022.01.019_bib24","doi-asserted-by":"crossref","unstructured":"Iida O, Takahara M, Soga Y, et\u00a0al. Vessel diameter evaluated by intravascular ultrasound versus angiography. J Endovasc Ther. Published online September 27, 2021. https:\/\/doi.org\/10.1177\/15266028211047946.","DOI":"10.1177\/15266028211047946"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:16:15Z","timestamp":1761848175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879822000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1936879822000711"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2022.01.019","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2022.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}